Evidence map›Paper›PMID 40922834›Full record

ArticleCureus2025

Acyclovir-Induced Nephrotoxicity: A Case Report.

Karim Chami, Khalid K Khaleq, Manal El Goubi, Mohmmed Moussaoui, Karim El Aidaoui

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karim ChamiAnesthesia and Critical Care, Hôpital Universitaire International Cheikh Khalifa Ibn Zaid/Faculty of Pharmacy, Mohammed VI University of Health Sciences, Casablanca, MAR.
Khalid K KhaleqAnesthesia and Critical Care, Centre Hospitalo-Universitaire Ibn Rochd/Université Hassan II de Casablanca, Casablanca, MAR.
Manal El GoubiAnesthesia and Critical Care, Hôpital Universitaire International Cheikh Khalifa Ibn Zaid/Faculty of Medicine, Mohammed VI University of Health Sciences, Casablanca, MAR.
Mohmmed MoussaouiAnesthesia and Critical Care, Centre Hospitalo-Universitaire Ibn Rochd/Université Hassan II de Casablanca, Casablanca, MAR.
Karim El AidaouiAnesthesia and Critical Care, Hôpital Universitaire International Cheikh Khalifa Ibn Zaid/Faculty of Medicine, Mohammed VI University of Health Sciences, Casablanca, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acyclovir is a widely used antiviral medication known for its potential nephrotoxic effects. These adverse effects may include acute kidney injury (AKI), acute tubulointerstitial nephritis, crystal-induced nephropathy, and, in rare cases, tubular dysfunction. While acyclovir is generally considered safe, nephrotoxicity can occur, particularly when administered at high doses or in dehydrated patients. We present the case of a 20-year-old woman who was previously in good health but developed acute kidney failure 48 hours after initiating intravenous acyclovir at a standard meningeal dose of 15 mg/kg every eight hours for suspected herpetic meningoencephalitis. Upon suspicion of drug-induced nephrotoxicity, acyclovir was discontinued, leading to a rapid improvement in renal function within 24 hours. This case highlights the importance of close monitoring in patients receiving acyclovir, particularly those at an increased risk of nephrotoxicity. To ensure early detection and intervention, it is crucial to perform regular renal function assessments, especially within the first 48 hours of treatment.

Indexed as

acute kidney disease‏acycloviracyclovir crystalsdrug-induced acute renal failurenephrotoxic drugs

Identifiers

PMID40922834
PMCPMC12414248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.